Ventus Therapeutics Significantly Expands its Presence in Montreal, Canada with Opening of a New Laboratory and Office Facility
July 16 2024 - 8:00AM
Business Wire
New 24,000-square-foot state-of-the-art
facility will facilitate the build-out of Ventus’ pipeline, enabled
by the vision to develop its ReSOLVE™ platform into a disruptive
drug discovery platform
Ventus Therapeutics, a clinical-stage biopharmaceutical company
utilizing its proprietary, machine learning-enabled, computational
chemistry platform, ReSOLVE™, and its deep protein science
expertise to develop differentiated small molecule therapeutics,
today announced the opening of a new laboratory and office facility
in Montreal, Canada. The new 24,000-square-foot state-of-the-art
facility more than doubles Ventus’ laboratory and office space in
Montreal and allows Ventus to strategically expand its R&D
capacity to enable the continued growth of its pipeline and further
development of its proprietary ReSOLVE™ platform.
“This new facility expands our presence in Montreal and augments
our existing facilities in Waltham, MA,” said Marcelo Bigal, M.D.,
Ph.D., President and CEO of Ventus. “The Montreal expansion will
provide us with an increased footprint that enables us to enhance
our R&D efforts, including further building out our ReSOLVE™
platform. ReSOLVE™ has already enabled three clinical-stage
compounds, including our first-in-clinic, orally administered cGAS
inhibitor, an important target for multiple autoimmune disorders
that has remained elusive to other drug discovery approaches.
ReSOLVE™ is a powerful ML-enabled drug discovery engine that can be
leveraged across multiple therapeutic areas to rapidly identify and
develop novel small molecule drugs for undruggable targets.”
The new facility serves as Ventus’ Montreal-based offices and
laboratories for its drug discovery and development organization,
including its medicinal chemistry, computational chemistry, DMPK,
and disease biology teams. This new facility represents the second
phase of Ventus’ global expansion and augments Ventus’
13,000-square-foot facility in Waltham, Massachusetts, which houses
Ventus’ corporate offices and laboratories for its structural
biology, biochemistry, protein sciences, molecular biology, and
cellular biology teams.
“We have already validated ReSOLVE™ for many targets, including
those deemed undruggable,” said Ventus Chief Scientific Officer,
Michael Crackower, Ph.D. “Our new lab facility will be pivotal in
advancing our vision to further develop ReSOLVE™ into a disruptive
small-molecule platform that will revamp traditional drug discovery
with unprecedented efficacy and speed.”
About Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical
company deploying deep protein science expertise and a proprietary
computational chemistry platform to develop novel small molecule
therapeutics for immunology, inflammation, and neurology disorders.
Using its proprietary drug discovery platform, ReSOLVE™, the
company screened its first target in 2020, selected three
development candidates in 2022, and advanced its two wholly-owned
product candidates into the clinic in 2023: VENT-03, a potent,
selective, oral cGAS inhibitor in Phase 1, and VENT-02, a potent,
brain-penetrant, oral NLRP3 inhibitor that has completed Phase 1.
In addition, Ventus has out-licensed VENT-01, a
peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These
programs exemplify Ventus’ robust discovery capabilities and focus
on differentiated programs for multi-indication immunology and
neurology targets. For more information, please visit
www.ventustx.com and engage with Ventus on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements involve known and unknown risks, uncertainties, and
other important factors that may cause Ventus’ actual results,
performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied
by the forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “would,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential,” or “continue” or the negative of these
terms or other similar expressions. All statements other than
statements of historical facts contained in this press release are
forward-looking statements, including statements regarding Ventus’
development plans and the expansion of Ventus’ R&D capacity to
enable the continued growth of its pipeline and further development
of its proprietary ReSOLVE™ platform. Because forward-looking
statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified and some of which are
beyond Ventus’ control, you should not rely on these
forward-looking statements as predictions of future events. Such
risks include, but are not limited to, the risk that Ventus is
unable to further advance VENT-02 and VENT-03 in clinical
development, obtain regulatory approval, and ultimately
commercialize VENT-02 and VENT-03, or experience significant delays
in doing so; that Ventus will require substantial additional
funding to finance its operations; that the development and
commercialization of pharmaceutical products is subject to
extensive regulation, and the regulatory approval processes of the
U.S. Food and Drug Administration and comparable foreign
authorities are lengthy, time-consuming, and inherently
unpredictable; and that Ventus’ success depends on its, its current
and future licensors’, and its exclusive licensees’ ability to
obtain, maintain, enforce, and protect its intellectual property
and its proprietary technologies. Forward-looking statements
included herein are based upon information available to Ventus as
of the date of this press release, and while Ventus believes such
information forms a reasonable basis for such statements, such
information may be limited or incomplete, and Ventus’ statements
should not be read to indicate that it has conducted an exhaustive
inquiry into, or review of, all potentially available relevant
information. The events and circumstances reflected in the
forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the
forward-looking statements. Except as required by applicable law,
Ventus does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances, or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715498574/en/
Media Dan Budwick 1AB dan@1abmedia.com